ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors

Cancer Research

Volumn 74, Issue 23, 2014, Pages 7079-7089

  Goetz, Eva M ^a,b   Ghandi, Mahmoud ^b   Treacy, Daniel J ^a   Wagle, Nikhil ^a,b   Garraway, Levi A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RAF PROTEIN; TRAMETINIB; UNCLASSIFIED DRUG; VALINE; VX 11E; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ALLELE; ARTICLE; CANCER INHIBITION; CELL VIABILITY; DRUG BINDING SITE; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MELANOMA; MUTATIONAL ANALYSIS; POINT MUTATION; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; HEK293 CELL LINE; MUTATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84916899372     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2073     Document Type: Article

References (39)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
2. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
4. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
5. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
6. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013;31:1767-74.
7. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014;4:94-109.
8. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor- Weiner A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014;4:61-8.
9. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7.
10. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90.
11. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-72.
12. Mandl M, Slack DN, Keyse SM. Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol Cell Biol 2005;25:1830-45.
13. Muda M, Theodosiou A, Rodrigues N, Boschert U, Camps M, Gillieron C, et al. The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases. J Biol Chem 1996;271:27205-8.
14. Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD, et al. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 2010;31:577-86.
15. Roskoski R Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012;66:105-43.
16. BioMed Valley Discoveries I. Phase I dose-escalation, safety, pharmacokinetic and pharmacodynamic study of BVD-523 in patients with advanced malignancies. In ClinicalTrialsgov [Internet]. Bethesda, MD: National Library of Medicine (2013). Available from: 〈https://clinicaltrials.gov/ct2/show/NCT01781429?term=bvd+523&rank=1〉. Accessed June 14, 2014.
17. Genentech. A dose-escalation study of GDC-0994 in patients with locally advanced or metastatic solid tumors. In ClincialTrialsgov [Internet]. Bethesda, MD: National Library of Medicine (2013). Available from: 〈https://clinicaltrials.gov/ct2/show/NCT01875705? term=gdc+0994&rank=1〉. Accessed June 14, 2014.
18. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007;109:5011-5.
19. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009;106:20411-6.
20. Broad-Novartis Cancer Cell Line Encyclopedia (CCLE). Version 2.17. Cambridge, MA: Broad Institute (2014). Available from: 〈http://broadinstitute.org/ccle/〈. Accessed September 5, 2014.
21. GENE-E [Internet]. Cambridge, MA: Broad Institute (2013). Available from: 〈http://www.broadinstitute.org/cancer/software/GENE-E/download.html〉. Accessed September 5, 2014.
22. Muteeb G, Sen R. Random mutagenesis using a mutator strain. Methods Mol Biol 2010;634:411-9.
23. Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J Med Chem 2009;52:6362-8.
24. COSMIC: Catalogue of somatic mutations in cancer [Internet]. v70. Hinxton, Cambridgeshire, UK. Wellcome Trust Sanger Institute (2014). Available from: 〈http://cancer.sanger.ac.uk/cancergenome/projects/ cosmic/〉. Accessed September 5, 2014.
25. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505:495-501.
26. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014;506:371-5.
27. Robinson MJ, Harkins PC, Zhang J, Baer R, Haycock JW, Cobb MH, et al. Mutation of position 52 in ERK2 creates a nonproductive binding mode for adenosine 5′-triphosphate. Biochemistry 1996;35:5641-6.
28. Bott CM, Thorneycroft SG, Marshall CJ. The sevenmaker gain-of-function mutation in p42 MAP kinase leads to enhanced signalling and reduced sensitivity to dual specificity phosphatase action. FEBS Lett 1994;352:201-5.
29. Chu Y, Solski PA, Khosravi-Far R, Der CJ, Kelly K. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 1996;271:6497-501.
30. Burkhard KA, Chen F, Shapiro P. Quantitative analysis of ERK2 interactions with substrate proteins: roles for kinase docking domains and activity in determining binding affinity. J Biol Chem 2011;286:2477-85.
31. Lee T, Hoofnagle AN, Kabuyama Y, Stroud J, Min X, Goldsmith EJ, et al. Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry. Mol Cell 2004;14:43-55.
32. Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther 2012;11:1143-54.
33. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014;508:118-22.
34. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013;494:251-5.
35. Arvind R, Shimamoto H, Momose F, Amagasa T, Omura K, Tsuchida N. A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation. Int J Oncol 2005;27:1499-504.
36. Guerreschi P, Scalbert C, Qassemyar A, Kluza J, Ravasi L, Huglo D, et al. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma. Melanoma Res 2013 Jul 10.
37. Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res 2013;19:5749-57.
38. Seghers AC, Wilgenhof S, Lebbe C, Neyns B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res 2012;22:466-72.
39. McArthur GA, Callahan J, Ribas A, Gonzalez R, Pavlick AC, Hamid O, et al. Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma. J Clin Oncol 32:5s, 2014 (suppl; abstr 9006∧).